纵横研报
Ticker Detail

605116.SHG

¥20.7+1.22% 奥锐特 Biotechnology
00Reports China 医疗健康
Aurisco Pharmaceutical Co Ltd
医疗健康 · 生物科技

Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides eplerenone, an API to treat cardiovascular diseases, lowering blood pressure, and treating heart failure; futicasone propionate, used for the treatment of asthma, respiratory tract diseases, and rhinitis; Tenofovir, an anti-infection used to treat AIDS and hepatitis B; pregabalin for the treatment of anti-epileptic, analgesic, and anti-anxiety purposes, as well as for neuralgia; abiraterone acetate to treat prostate cancer; and dydrogesterone, to treat endogenous for women's heath. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.

MARKET 市值 8.09B CNY PE 20.7x 52W ¥17.79 – ¥34.98 EODHD · Q 2026-03-31 · 同步 2026-07-12
QUALITY PEG 营收 YoY -3.2% ROE 15.3% 营业利润率 23.5% 净利润率 23.4%
ANALYST 股息率 1.77%

暂无相关研报

数据库中已收录该标的的基本面数据,可发起一份定制研报。

CUSTOM RESEARCH · 定制研报 没找到完全契合的标的?让我们替你做一份。 告诉我们你关心的标的与偏好,1 个工作日内在站内上线。 开始定制